Free accessResearch articleFirst published online 2007-12
Beneficial effects of ramipril on myocardial diastolic function in patients with type 2 diabetes mellitus,normal LV systolic function and without coronary artery disease: a prospective study using tissue Doppler
Angiotensin-converting enzyme (ACE) inhibitors can improve cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM). Myocardial diastolic function (Ve) is a known marker of cardiovascular prognosis. It could potentially indicate the effects of preventive therapy if evaluated by tissue Doppler. We tested the hypothesis that treatment with the ACE inhibitor ramipril has beneficial effects on Ve.
In this study, 16 subjects on insulin therapy (eight receiving 10 mg ramipril/day compared to eight matched controls who were not treated with an ACE inhibitor) were followed up for a period of nine months. Myocardial and vascular function were assessed by tissue Doppler and ultrasound.
In the ramipril group, Ve improved significantly after nine months of treatment (7.8±0.9 cm/s to 8.6±0.9 cm/s, p<0.04). Systolic blood pressure and intima media thickness (IMT) demonstrated a trend towards improvement. In controls, Ve remained unchanged and there was a trend towards deterioration in stiffness index beta (p<0.07).
In conclusion, the observed improvement of myocardial diastolic function with ramipril in patients with T2DM is an encouraging result. It might contribute to the overall improvement that has been observed with hard cardiovascular end points.
1. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet2000;355:253–9.
2.
2. Chaturvedi N.HOPE and the extension of indications for ACE inhibitors. Lancet2000;355:246–7.
3.
3. Celentano AVaccaro O, Tammaro Pet al.Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Am J Cardiol1995;76:1173–6.
4.
4. Raev DC.Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type 1 diabetic patients. Diabetes Care1994;17:633–9.
5.
5. Diamant MLamb HJ, Groeneveld Yet al.Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol2003;42:328–35.
6.
6. Fang ZYYuda S, Anderson V, Short L, Case C, Marwick HT.Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol2003;41:611–17.
7.
7. von Bibra H, Hansen A, Dounis V, Bystedt T, Malmberg K, Rydén L.Augmented metabolic control improves myocardial diastolic function and perfusion in patients with type 2 diabetes mellitus. Heart2004;90:1483–4.
8.
8. Bella JNPalmieri V, Roman MJet al.Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults. The Strong Heart Study. Circulation2002;105:1928–33.
9.
9. Wang MYip GW, Wang AYet al.Peak early diastolic mitral annulus velocity by tissue Doppler imaging adds independent and incremental prognostic value. J Am Coll Cardiol2003;43:820–6.
10.
10. Hansen AJohansson BL, Wahren J, von Bibra H.Beneficial effects of C-peptide on myocardial function in patients with type 1 diabetes. Diabetes2002;51:3077–82.
11.
11. Fukuta HSane DC, Brucks S, Little CW.Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation2005;112:357–63.
12.
12. Hoffmann UGlobits S, Stefenelli T, Loewe C, Kostner K, Frank H.The effects of ACE inhibitor therapy on left ventricular myocardial mass and diastolic filling in previously untreated hypertensive patients: a cine MRI study. J Magn Imaging2001;14:16–22.
13.
13. Nagueh SFMiddleton KJ, Kopelen HA, Zoghbi WA, Quinones AM.Doppler tissue imaging: a non-invasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol1997;30:1527–33.
14.
14. von Bibra H, Tuchnitz A, Klein A, Schneider-Eicke J, Schömig A, Schwaiger M.Regional diastolic function by pulsed Doppler myocardial mapping for the detection of left ventricular ischemia during pharmacologic stress testing – a comparison with stress echocardiography and perfusion scintigraphy. J Am Coll Cardiol2000;36:444–52.
15.
15. von Bibra H, Thrainsdottir IS, Hansen A, Dounis V, Malmberg K, Rydén L.Tissue Doppler imaging for the detection and quantitation of myocardial dysfunction in patients with type 2 diabetes mellitus: A methodological study. Diabetes Vasc Dis Res2005;2:24–30.
16.
16. Avgeropoulou CIllmann A, Schumm-Draeger PM, Kallikazaros J, von Bibra H.Assessment of arterio-ventricular coupling in well controlled type 2 diabetes mellitus and controls by tissue Doppler and wave intensity approach. Br J Diabetes Vasc Dis2006;6:271–8.
17.
17. Simon AGariepy J, Chironi G, Megnien JL, Levenson J.Intima-media thickness: a new tool for diagnoses and treatment of cardiovascular risk. J Hypertens2002;20:159–69.
18.
18. Sugawara MNiki K, Furuhata H, Ohnishi S, Suzuki S.Relationship between the pressure and diameter of the carotid artery in humans. Heart Vessels2000;15:49–51.
20. Greenberg BQuinones MA, Koilpillai Cet al.Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Circulation1995;91:2563–81.
21.
21. St John Sutton M, Pfeffer M, Plappert Tet al.SAVE Investigators. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: The protective effects of captopril. Circulation1994;89:68–75.
22.
22. Lonn EShaikholeslami R, Yi Qet al.Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction. J Am Coll Cardiol2004;43:2200–06.
23.
23. Philbin EFRocco TA, Lindenmuth NW, Ulrich K, Jenkins LR.Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting-enzyme inhibitors. Am J Med2000;109:605–13.
24.
24. von Bibra H, Siegmund T, Hansen A, Jensen J, Schumm-Draeger P-M.Augmentation of myocardial function by improved glycaemic control in patients with type 2 diabetes mellitus. Dtsch Med Wochenschr2007;132:1–6.
25.
25. Huang YWalker KE, Hanley F, Narula J, Houser SR, Tulenko NT.Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet. Circulation2004;109:97–102.
26.
26. Oki TTabata T, Yamada Het al.Left ventricular diastolic properties of hypertensive patients measured by pulsed tissue Doppler imaging. J Am Soc Echocardiogr1998;11:1106–12.
27.
27. Forman DEManning DJ, Hauser R, Gervino GV, Evans WJ, Wei EJ.Enhanced LV diastolic filling associated with long term endurance training. J Gerontol1992;47:M56–M58.
28.
28. Dounis VSiegmund T, Jensen J, Hansen A, Schumm-Draeger PM, von Bibra H.Global myocardial perfusion and diastolic function are impaired to a similar extent in patients with type 2 diabetes mellitus and in patients with coronary artery disease – evaluation by contrast echocardiography and pulsed tissue Doppler. Diabetologia2006;49:2729–40.
29.
29. Fukuta HSane DC, Brucks S, Little CW.Statin therapy may be associated with lower mortality in patients with diastolic heart failure - a preliminary report. Circulation2005;112:357–63.
30.
30. Jandeleit-Dahm KAM, Tikellis C, Reid CM, Johnston CI, Cooper ME.Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens2005;23:463–73.
31.
31. Dzau V.Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension2003;37:1047–52.
32.
32. Koh KQuon MJ, Han SHet al.Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes mellitus. Hypertension2005;45:1088–93.
33.
33. Haynes WGNoon JP, Walker BR, Webb JD.Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens1993;11:1375–80.
34.
34. Muniyappa RSrinivas PR, Ram JL, Sowers RJ.Glucose-induced inhibition of inducible nitric oxide synthase in vascular smooth muscle cells; role of protein kinase Cß II and Rho;J Diabet Complications2001;15:22–7.
35.
35. Manolis AJIraklianou S, Pittaras Aet al.Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy. Am J Hypertens2005;18:18–22.
36.
36. Salomaa VRiley W, Kark JD, Nardo C, Folsom AR.Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC study: Atherosclerosis Risk in Communities Study. Circulation1995;91:1432–43.
37.
37. van Dijk RA, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD.Brachial artery pulse pressure and common carotid artery diameter: mutually independent associations with mortality in subjects with a recent history of impaired glucose tolerance. Eur J Clin Invest2001;31:756–63.
38.
38. Mottram PMHaluska BA, Leano R, Carlier S, Case C, Marwick HT.Relation of arterial stiffness to diastolic dysfunction in hypertensive heart disease. Heart2005;91:1551–6.
